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Flora,3 Eino Hietanen,4 Anne-Marie Camus,1 Marcel
Castegnaro,1 Kroum Alexandrov,' Margarita Rojas,'
Rodolfo Saracci,1 and Carlo Giuntini2
Cigarette smoking is the strongest risk factor for lung cancer, but genetically determined variations in the
activities of pulmonary enzyme that metabolize tobacco-derived carcinogens may affect individual risk. To
investigate whether these enzymes (e.g., CYPIA-related) can serve as markers for carcinogen-DNA damage,
lung tissue specimens were taken during surgery from middle-aged men with either lung cancer or non-
neoplastic lung disease. Phase I [aryl hydrocarbon hydroxylase (AHH), ethoxycoumarin O-deethylase
(ECOD)] and ph;e-Ceipoxide hydrolase, UDP-glucuronosyltransferase, glutathioneS-transferase) enzyme
activities, glugtathione and malondialdehyde contents were determined in lung parenchyma and/or bronchial
tissues;-some samples were also analyzed for DNA adducts, using 32P-postlabeling. The data were then
analyzed for the following: a) differences in metabolic profiles between bronchial and parenchymal lung
tissue; b) the effect ofrecent exposure to tobacco smoke on enzyme inducibility andbenzo[a]pyrene metabo-
lism;c) differences in enzyme inducibility between lung cancer and non-lung cancerpatients; d) the effect of
smoking on metabolism of mutagens in vitro; e) pulmonary DNA adduct levels and AHH activity in lung
parenchyma of smokers and ex-smokers; I) lipid peroxidation products in lung tissue from lung cancer and
non-lung cancer patients, as related to smoking habits and degree of airway obstruction; and g) prognostic
value of AHH pulmonary activity in lung cancer patients. The results demonstrate a pronounced effect of
tobacco smoke on pulmonary metabolism ofxenobiotics and prooxidant state and suggest the existence ofa
metabolic phenotype at higher risk for tobacco-associated lung cancer.
Introduction
Cigarette smoking is the strongest risk factor for lung
cancer so far identified (1), but the variation in individual
cancer risk suggests that host factors, either acquired or
inherited, play a role (2-5).
Inducibility of aryl hydrocarbon hydroxylase (AHH)
activityinmitogen-stimulatedlymphocyteshaspreviously
been associated with a higher risk of lung cancer in
smokers (6-8).
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In 1982, we started to test the hypothesis that the
activity of pulmonary enzymes such as AHH (which
reflect mainly cytochrome P450 IAl-mediated reactions)
and otherdrug-metabolizing enzymes, known tobepartly
under genetic control, reflects the rates of metabolic
activation and inactivation oftobacco-related carcinogens
and could therefore serve as a marker for the extent of
carcinogen-derived DNAdamage that accumulates in the
lungs of smokers. In the past, there have been meth-
odological problems with the lymphocyte AHH-induction
assay in which individual enzyme (AHH) activity was
generally tested in nontarget cells, such as circulating
lymphocytes. We therefore set up a multicenter study
(involving the University ofPisa, Italy; the University of
Genoa, Italy; and the International Agency for Research
on Cancer, Lyon, France) to relate interindividual varia-
tions in pulmonary carcinogen metabolism, measured in
lungsamplesfreshlyobtained atsurgeryfromlungcancer
and noncancer patients, to cancer susceptibility.BARTSCH ET AL.
This article briefly summarizes the major findings of
the case-control study, which have been presented in
detail together with a more complete bibliography else-
where (9-15).
Subjects and Methods
Study Subjects
If not stated otherwise, study subjects were male
patients undergoing surgery for lung cancer (n = 60) or
otherthoracicdisease(n = 20)attheUniversityHospital,
Pisa, Italy. None of the patients were receih ig drugs
known to be human enzyme inducers, and none of the
cancer patients had received prior X-ray treatment or
chemotherapy. Data were collected regarding pulmonary
and/or extrapulmonary diseases and smoking habits.
Patients were divided into smokers, ex-smokers and non-
smokers; the latter twowere defined as subjects who had
refrained from smoking for more than 6 months, and had
never smoked, respectively. Due to limitations in the
amount oftissue obtained, not all end pointswere investi-
gated for every subject, and results from subsets are
described in the text.
Preparation ofLung Postmitochondrial
(S-12) Fractions
Specimens of peripheral lung parenchyma and, for a
subset ofpatients, bronchial tissue sampleswere obtained
at surgery from each patient. In lung cancer patients,
tissue was taken from a location as distant as possible
from the tumor. Each specimen was kept in cold 0.15 M
KCl solution until homogenization, which was always car-
ried out within 1-2 hr after surgery and S-12 fractions
were prepared as described previously (10). For some
studies, lung microsomes were prepared according to
standard procedures.
Determination ofEnzyme Activities
Enzyme activities were determined as described by
Petruzzelli et al. (10).AHH, ethoxycoumarin O-deethylase
(ECOD), epoxide hydrolase (EH), UDP-glucuronosyl-
transferase (UGT), and glutathione S-transferase (GST)
activities and glutathione (GSH) and malondialdehyde
(MDA) contents were measured in duplicate in coded
samples. MDA, an indicator of lipid peroxidation, was
determined as described elsewhere (16). For some lung
samples, themicrosomal conversion of(-)benzo[a]pyrene
(BP)-7,8-diol into tetrols was quantified using high-
performance liquid chromatography and fluorescence
detection.
Mutagenicity Assays
The efficiency of lung S-12 fractions in activating pro-
mutagens or in decreasing the mutagenicity of directly
acting mutagens was investigated in the Ames reversion
test, as described by De Flora et al. (9).
32P-Postlabeling
DNA adducts were isolated by 32P-postlabeling assay
after enrichment of adducted nucleotides, using dephos-
phorylation ofnormal nucleotides with nuclease P1, chro-
matographic clean-up, and transfer chromatography and
separation, as described by Geneste et al. (14). Normal
nucleotides and adductswere quantified usingliquid scin-
tillation counting. The adduct level was calculated on the
basis ofthe assumption that the adducts were completely
resistant to 3'-dephosphorylation by nuclease P1.
Airway Obstruction
This was assessed by flow-volume spirometry curves.
The results were expressed as a percentage of the pre-
dictedvalues derived from a general population sample in
Italy (17).
Statistical Analysis
If not otherwise stated, conventional methods of one-
way analysis of variance were used for comparisons
betweengroups (withtheuseofcovariateswhenappropri-
ate), and simple bivariate linear regression methods were
used for correlation analysis. Datawere transformed log-
arithmically whenever required, to normalize their dis-
tribution.
Results and Discussion
Characteristics ofStudy Subjects
Lung cancer patients (54.5 years of mean age) were
significantly older (p < 0.001) than noncancer patients
(45.7 years) and the mean number ofpack-years (corres-
ponding to the number ofcigarettes smoked per day per
yearofsmoking/20) was significantly higher (48.5 + 26.3
vs. 27.7 ± 21.6; p < 0.01) in cancer patients than in non-
cancer patients. Of the lung cancer cases, 25 had
squamous-cell carcinoma, 16 had adenocarcinomas, 9 had
undifferentiated large-cell carcinomas and 2 had undif-
ferentiated small-cell carcinomas. The cancer-free con-
trols had miscellaneous pathological conditions, as
described previously (10).
Comparison ofPhase I and II Drug-
metabolizing Enzymes in Human Bronchial
and Lung Parenchymal Tissue
Pulmonary drug metabolism was investigated by mea-
suring the activities and levels of AHH, EH, GST, UGT
andGSHinS-12fractions ofbronchial tree andperipheral
lung parenchyma from 21 patients, all smokers or ex-
smokers (11). When compared to bronchial preparations,
lung parenchyma contained considerably higher con-
centrations ofreduced GSH and significantly higher EH
activity. Enzyme activities in peripheral lung and bron-
chial preparations from the same patient (a subset of10)
were correlated positively (AHH: r = 0.77, p < 0.009);
GST: r = 0.83,p < 0.01; EH: r = 0.63,p = 0.07; UDPGT:
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r = 0.73, p < 0.1). These results indicate that there is a
common genetic control ofthese enzymesindifferentcells
and tissues from one individual.
As comparisons of parenchymal and bronchial tissue
from the same patient (either cancer or noncancer)
revealed no statistically significant difference (except in
EH activity and for GSH level), lung parenchymal tissue
specimens were analyzed further in detail.
Differential Pulmonary Enzyme Induction
in Cancer and Noncancer Patients and the
Effect ofSmoking
AHH, ECOD, EH, GST, and UGT activities and GSH
andMDAcontentsweredeterminedinS-12fractionsfrom
nontumorous parenchymal tissues taken during surgery
from middle-aged men with (n = 54) orwithout (n = 20)
lung cancer (10). Interindividual differences in enzyme
activities ranged from 11- to 440-fold, and GSH content
varied by 30-fold. The values showed unimodal distribu-
tions (all subjects). AHH, ECOD, EH, and UGT activities
were significantly and positively correlated with each
other implying similar regulatory control of their
expression (Table 1). No difference was found in enzyme
activities or GSH content between cancer and non-cancer
patients or between smokers and nonsmokers. When the
number of days since stopping smoking was considered,
however, a significant increase in AHH, EH, and UGT
activities and a smaller, but significant, decrease in GST
activity were found in smokers, as compared to non-
smokers. The activities ofthese enzymes returned to the
level found in nonsmokers within several weeks, revealing
along-lasting effect ofsmoking. Cancer patients who had
been recent smokers (within 30 days before surgery) had
significantly(p < 0.01)inducedAHHandECODactivities
(mean: about 2- and 7-fold, respectively) when compared
with smoking noncancer patients (Fig. 1).
In a subsequent study the inducing effect of recent
smoking on carcinogen metabolism in the lung was con-
firmed in another group oflung cancer patients (obtained
Iable 1. Relationships among human lung parenchymal
AHH, ECOD, EH, UGT, and GST activities.a
Correlation coefficient
ECOD EH UGT GST
AHH 0.50* 0.48* 0.28t -0.55
(45)b (60) (59) (60)
ECOD 0.43t 0.48* -0.27c
(43) (39) (43)
EH 0.44* -0.25t
(63) (69)
UGT -0.22
(63)
Abbreviations: AHH, aryl hydrocarbon hydroxylase; ECOD, ethox-
ycoumarin O-deethylase; EH, epoxide hydrolase; UGT, UDP-
glucuronosyltransferase; GST, glutathione S-transferase
aData from Petruzzelli et al. (10).
bNumber ofdeterminations available.
*p < 0.001.
tp < 0.05.
tp < 0.01.
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FIGURE1.Enzymeinductionofpulmonaryarylhydrocarbonhydroxylase
(AHH) and ethoxycoumarin O-deethylase (ECOD) activities in lung
cancer patients (LC) who were recent smokers (within 30 days before
surgery), when compared with noncancer patients who smoked (NLC).
Data extracted from Petruzzelli et al. (10); mean (± SEM) are plotted.
from the University Central Hospital, Helsinki, Finland).
Metabolism ofBP by lung tissues in vitro was measured
byanalyzingthemetabolicproductsof(-)BP-7,8-diol,i.e.,
BP-tetrols (18). The stereoselective activation of BP has
been implicated as an important factor in the car-
cinogenesis of (+ )anti-BP-diol epoxide [(+ )r-7,t-8-
dihydroxy-t-9,10 oxy-7,8,9,10-tetrahydro-BP], the oxida-
tion product of (-)BP-7,8-diol. BP-anti-tetrols, mostly
consisting of r-7,c-10,t-8,t-9-tetrahydroxy-7,8,9,10-
tetrahydro-BP, were measured by HPLC/fluorescence
detection (19) afterincubationwithlungmicrosomes from
lung cancer patients (smokers, ex-smokers and non-
smokers). Recent smokers had significantly (4- to 7-fold)
higher metabolic activity, expressed as picomole tetrols/
hr/mgprotein,thanex-smokersandnonsmokers. Pulmon-
ary AHH activity was correlated with tetrol formation in
the same lungmicrosomal sample (r = 0.67, p < 0.01).
In another sub-group oflung cancer patients (n = 25;
from UniversityCentral Hospital, Helsinki, Finland), pul-
monary AHH activity also showed a good correlation
(r = 0.59; p < 0.01) with the intensity of immunohisto-
chemical stainingforcytochrome P450IAbyamonoclonal
antibody (raised against 3-methylcholanthrene-inducible
rat cytochrome P450) in human lung tissue sections.
Smoking and peripheral types of lung cancer were
positively related to high levels ofpulmonary cytochrome
P450IA, probably reflecting high rates of induction by
smoking (20).
These results are supported by independent findings:
AHH activity in normal human cells induced with poly-
cyclic aromatic hydrocarbons was closely correlated with
the expression ofthe structural CYPlAl gene (21). Active
smoking has been found to be correlated positively with
the expression of CYPlAl mRNA in human lung tissue,
and the gene expression was no longer detected 6 weeks
after stopping smoking (22).
The results reinforce previous circumstantial evidence
fromstudies ofAHH inductioninlymphocytes (see Intro-
duction) that differential inducibility of pulmonary
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enzymes (CYPlAl expression) in tobacco smokers is
related to lung cancer risk in smokers.
Pulmonary Metabolism ofMutagens As
Related to Drug-metabolizing Enzyme
Activities and GSH Content in Lung
Parenchyma
The S-12 fractions of lung peripheral parenchyma
obtained from lung cancer (n = 60) and noncancer
patients (n = 20) were assayed for their ability either to
convert pro-mutagens into bacterial mutagens or to
decrease the activity of directly-acting mutagens in the
Ames reversion test (9). In this assay, S-12 preparations
were ineffective in activating N-nitrosomorpholine,
3-methylcholanthrene, BP orBP-7,8-diol. Borderline, spo-
radic activationwas seenwithcigarette smoke condensate
and weak but frequent activation with 2-aminofluorene,
2-amino-3,4-dimethylimidazo[4,5-fpquinoline and cyclo-
phosphamide. Pulmonary metabolism consistently de-
creased the mutagenicity of directly-acting mutagens,
sodium dichromate, the acridine and nitrogen mustard
derivative ICR 191, epichlorohydrin, and 4-nitroquinoline
N-oxide. The mutagenicity of the same compounds was
also decreased, although less efficiently, by the corres-
ponding preparations ofbronchial tree, as assessed with
26 specimens (23). Ingeneral, smokinghabitswereassoci-
ated with stimulation ofdetoxifying mechanisms for some
ofthe directly-acting mutagens investigated.
Significant correlations were seen between several bio-
chemical and enzymic parameters andmutagenicitywhen
evaluated in the same lung specimens (15).
Correlation between Pulmonary DNA
Adduct Level and AHH Activity in Lung
Parenchyma ofSmokers and Ex-smokers
In order to test the hypothesis that pulmonary drug-
metabolizing enzymes (expressed by a particular meta-
bolic phenotype or genotype) reflect the rate ofmetabolic
activation orinactivation oftobacco-related carcinogens in
the lungs of smokers, and thus can serve as markers for
the internal dose of DNA-reactive metabolites generated
intargettissue,wedeterminedthelevelofDNAadductsin
lungparenchymaofsmokers andwhetherthese are corre-
latedwithAHHactivitRTinthe sametissue. Thenumberof
DNA adducts per 10 nucleotides was determined by
scintillation counting after 32P-postlabeling analysis
(14,24). Microsomal fractions of the same lung specimen
were assayed for AHH activity by a fluorimetric method.
Smokers had significantly higher levels of DNA adducts
per 108 nucleotides (mean + SD: 5.38 + 3.19) than ex-
smokers (1.09 + 0.84). AHH activity (pmole 3-HO-BP/
min/mg protein) was significantly higher (p < 0.05) in
recent smokers (0.26 + 0.26) who smoked until 1 week
before surgerythaninthosewhohadstopped smokingfor
more than 7 days (0.11 + 0.11). A positive, linear correla-
tion between DNA adduct levels and AHH activity
(r = 0.69; p = 0.001; n = 19) was found in smokers. Such
a relationship, if renerally true (keeping in mind the
limitations of the 2P-postlabeling assay and the small
number of subjects), could explain why AHH activity or
inducibility expressed by certain metabolic phenotypes or
genotypes appears to be a crude marker for lung cancer
risk in smokers, as seen in earlier studies (see "Introduc-
tion"). The extent of DNA damage generated in target
cells of a smoker's lung would be expected to differ
between the "AHH-inducible" and "noninducible" phe-
notype.Althoughthisremainstobeproven,wehavefound
thatthe (mean) levels ofpulmonaryAHH and ECODwere
significantly higher (about 2- to 7-fold) in lung cancer
patients who had smoked within 30 days before surgery
thanincancer-freesubjectswithasimilarsmokinghistory
(10).
Pulmonary Lipid Peroxidation Products in
Cigarette Smokers and Lung Cancer
Patients
Cigarette smoke may also enhance lung carcinogenesis
byfree radical-mediated reactions. Such radicals are pre-
sent in smoke and can attack DNA directly or cause
membrane damage, and they can activate oxygen (25), a
process that has been associated with tumor promotion.
We therefore studied lipid peroxidation in lung tissues
from a subset oflung cancer and noncancer patients and
itsrelationshipswith smokinghabitsanddegree ofairway
obstruction (12). Specimens of peripheral lung par-
enchyma, free of tumorous tissue, were taken, and the
(MDA) content was measured in the S-12 fractions. Air-
way obstruction was assessed by flow-volume curves, and
datawereexpressedaspercentageofthepredictedvalues.
Cigarettes smoked were expressed as pack-years. Lung
cancer patients and controls did not differ with regard to
MDA content, age, or number of pack-years. FEE75,85
(forced expiratoryflowbetween 75and 85% offorcedvital
capacity) and MEF75 (maximal expiratory flow at 75% of
forced vital capacity) were significantly lower in cancer
than in noncancer patients (p = 0.05). MDA content was
inversely correlatedwith the number ofdays patients had
refrained from smoking (r = 0.66, p < 0.01), and was
higher in recent smokers (i.e., people who had smoked
during the last 30 days before surgery) than in the other
patients (p < 0.05). Amongthe recent smokers, MDA con-
tent was higher in cancer patients than in noncancer
patients (p = 0.059). When patients were divided into
"high MDA" and "low MDA" groups, MEF75 was much
lower in the high MDA group than in the low MDA group
(p < 0.01). These results suggestthat an enhanced level of
prooxidant state in the lungs is associated with recent
cigarette smoking; b) cancerpatients are more prone than
noncancer patients to oxidative stress; c) MDA level and
degree of small airway obstruction were associated and
differed between cancer and noncancer patients, even
though these groups did not differ in the percentage of
recent smokers; and d) a common free-radical-mediated
pathwaymaycontribute tobothlung cancerinduction and
small airway obstruction.
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Prognostic Value ofPulmonary AHH
and EH Activities in Patients with
Tobacco-related Lung Cancer
We have conducted an analysis on use of pulmonary
drug-metabolizing enzymes (AHH, EH) as prognostic
markers in male lung cancer patients. Asubset of50 lung
cancer patients who had undergone thoracic sugery was
used. The activity ofparenchymal AHH and EH in homo-
genates of nonneoplastic surgical lung specimens (see
previous section)was comparedwiththepatients' survival
after surgery. When the crude mortality percentages at 1
and 2 years were calculated in relation to AHH and EH
activity, subdivided into quarters of the distribution,
higher mortality was related to higher enzyme activities
(Table 2). Subjects in the first and fourth quarters ofthe
distribution showed significant differences in 1-year sur-
vival in relation to AHH (p = 0.05) and EH (p < 0.01)
activities. This relationship could not be accounted for by
age, cumulative lifetime smoking, recent or continuing
smoking, stage, or histological type ofdisease.
The molecular mechanisms bywhich AHH or EH may
be related to the prognosis oflung cancerpatients remain
obscure. Both enzyme activities canbeinducedbytobacco
smoke, and they are positively correlated with each other
(r = 0.47, p < 0.001). This could explain, at least in part,
the concordance ofresults found here fortheirprognostic
value; however, our data are in agreement with those on
the prognostic value of intratumoral AHH activity in
breast cancer patients (26), although the etiology and
pathophysiologyofthesetumors arecertainlydifferent. It
is conceivable that in lung cancer patients higher AHH
activitywould reflect a high totalbodyburden oftobacco-
related carcinogens, including enzyme-inducing sub-
stances that bind to the Ah receptor in lung tissue. Such
substances are easily stored in adipose tissue, are depos-
ited in the lung, and might suppress immunological func-
tions, possibly leading to easier metastasis and faster
growth oftumors. Itis alsoplausible thattheAh receptor
controls not only CYPAl1 expression (AHH activity) but
also gene functions unrelated to drug metabolism which
are involved in growth regulation and tumor promotion
Table 2. Mortality oflung cancer patients 1 and 2 years after
surgery according to their pulmonary AHH and EH activity.a
AHH activity, pmole/min/mg, protein
Number ofpatients
Deceased after 1 year, %
Deceased after 2 years, %t
Enzyme activity (distribution)
1st Quarter 4th Quarter
0-0.006 0.039-0.280
12 11
8 55
25 73
EH activity, nmole/min/mg, protein 0.05-0.121 0.251-0.540
Number ofpatients 12 12
Deceased after 1 year, %f 0 58
Deceased after 2 years, %§ 25 75
aFrom Bartsch etal. (13). Symbols denote significance ofthedifference
in mortalitybetween subjects in the 1st and 4th quarters ofthe distribu-
tion (chi-square with Yate's correction).
*Chi-square = 3.81, p = 0.05.
tChi-square = 3.50, p < 0.10.
tChi-square = 7.26, p < 0.01.
§Chi-square = 4.17, p < 0.05.
(27). In addition or alternatively, aromatic hydrocarbons
and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-like sub-
stances reported to be presentin tobacco smoke (28) may
not only bind to the Ah receptor but could also interact
with other cell growth-controlling receptors (e.g.,.
estrogen, epidermal growth factor and glucocorticoid
receptors or other TCDD-responsive genes) leading to
faster outgrowth between lung tumors.
Taken together, our results reinforce previous circum-
stantial evidence from lymphocyte assays that CYPlAl
expression (inducibility of pulmonary AHH) in tobacco
smokers is associated with cancer risk. Our preliminary
results on the positive relationship between pulmonary
DNAadductsandAHHactivitysuggestamechanisticbasis
for the difference in risk between certain metabolic pheno-
and genotypes for tobacco-induced lung cancer: Among
smokers with the same cigarette consumption, the AHH-
induciblephenotypewouldbepredictedtogenerate ahigher
amountofcertaincarcinogen-DNAdamageintargetcellsof
the lungs, a hypothesis that remains to be confirmed.
Enzyme induction by smoke constituents would be
expected to increase the formation of both reactive and
inactivemetabolites insmokers'lung. However,ithasbeen
suggested that CYPlA-mediated insertion of oxygen into
conformationally hindered positions in planar substrates,
such as polycyclic aromatic hydrocarbons and aromatic
amines, results in the formation ofreactive intermediates
which arepoorsubstrates for subsequent conjugation and
detoxication (29). In contrast, oxygenation at conforma-
tionally unhindered positions of chemicals by other
cytochromes (e.g., CYP2B) is followed by rapid conjuga-
tion that results in detoxication. It is therefore likely that
certain tobacco smoke-derived carcinogen adducts
decrease in lung DNA while others increase as a conse-
quence ofenzyme induction.
The conclusion that a genetic component is involved in
the etiology of lung cancer is consistent with recent
molecular studies onCYPpolymorphisms andlungcancer
risk: In one three-generation family of15 individuals, the
high CYP1A1-inducible phenotype cosegregated with a
polymorphic site downstream fromthe CYP1A1 gene (30).
An association between this polymorphism and increased
riskfortobacco-associated squamous-celllungcancerwas
reported in a Japanese population (31), but not in a Nor-
wegian population (32). Interestingly, the susceptible
CYPlAl genotype contracted squamous-cell carcinoma
with a lower number of cigarettes than other genotypes
(33). In addition, an association was found between
restriction fragmentlengthpolymorphism in the CYP2E1
gene and susceptibility to cigarette-related lung cancer
(34), possiblyreflectingvariations in the metabolic activa-
tion ofcarcinogenic nitrosamines known to be present in
tobacco smoke.
These results indicate thatreliable phenotyping and gen-
otyping assays should be developed and applied andjustify
detailed studies on CYPlA4 gene in order to identify high-
risk subjects for lung cancer among smokers. Such people
once identified might be convinced to quit their habit or
offered an intensive, personalized smoking cessation pro-
gram.
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